Realtime-Estimate
Andere Börsenplätze
|
% 5 Tage | % 1. Jan. | ||
141.3 USD | -0.68% | +3.73% | +7.19% |
Kurzporträt
Mitarbeiterzahl: 1 448
Umsatz nach Geschäftsbereich
USD in Millionen | 2022 | Gewichtung | 2023 | Gewichtung | Delta |
---|---|---|---|---|---|
Pharmaceuticals
100,0
%
| 1 489 | 100,0 % | 1 887 | 100,0 % | +26.76% |
Umsatz je Region
USD in Millionen | 2022 | Gewichtung | 2023 | Gewichtung | Delta |
---|---|---|---|---|---|
United States
100,0
%
| 1 489 | 100,0 % | 1 887 | 100,0 % | +26.76% |
Manager
Manager | Titel | Alter | Seit |
---|---|---|---|
Kevin Gorman
FOU | Founder | 66 | 01.01.92 |
Director of Finance/CFO | 44 | 01.11.17 | |
Jude Onyia
CTO | Chief Tech/Sci/R&D Officer | 60 | 30.11.21 |
Eiry Roberts
CTO | Chief Tech/Sci/R&D Officer | 60 | 08.01.18 |
Bill Wilson
COO | Chief Operating Officer | - | 01.09.96 |
Chief Tech/Sci/R&D Officer | 65 | 01.01.93 | |
Gary Lyons
BRD | Director/Board Member | 73 | 01.02.93 |
Todd Tushla
IRC | Investor Relations Contact | - | - |
Ingrid Delaet
LAW | General Counsel | 58 | 01.01.21 |
David Boyer
PRN | Corporate Officer/Principal | 44 | 30.09.19 |
Aufsichtsräte
Aufsichtsräte | Titel | Alter | Seit |
---|---|---|---|
Stephen Sherwin
BRD | Director/Board Member | 75 | 01.04.99 |
George Morrow
BRD | Director/Board Member | 72 | 01.10.15 |
Kevin Gorman
FOU | Founder | 66 | 01.01.92 |
Christine Poon
BRD | Director/Board Member | 71 | 11.07.23 |
Chairman | 76 | 08.02.10 | |
Richard Pops
BRD | Director/Board Member | 62 | 01.04.98 |
Gary Lyons
BRD | Director/Board Member | 73 | 01.02.93 |
Leslie Norwalk
BRD | Director/Board Member | 58 | 01.04.98 |
Shalini Sharp
BRD | Director/Board Member | 49 | 03.02.20 |
Johanna Mercier
BRD | Director/Board Member | 54 | 15.04.21 |
Anteilsklasse
Vote | Menge | Streubesitz | Konzerneigene Aktien | Total Float | |
---|---|---|---|---|---|
Aktie A | 1 | 100 637 227 | 98 829 670 ( 98,20 %) | 0 | 98,20 % |
Unternehmensbesitz
Name | Aktien | % | Bewertung |
---|---|---|---|
VOYAGER THERAPEUTICS, INC. 15,79% | 8 575 316 | 15,79% | 63 628 845 $ |
Unternehmenskontakt
Neurocrine Biosciences, Inc.
6027 Edgewood Bend Court
92130, San Diego
+858 617 7600
http://www.neurocrine.comSektor
Verlauf des Gewinns je Aktie
% 1. Jan. | Kap. | |
---|---|---|
+7.19% | 14.32 Mrd. | |
+9.86% | 115 Mrd. | |
+11.78% | 106 Mrd. | |
-2.59% | 21.96 Mrd. | |
-12.69% | 21.87 Mrd. | |
-5.29% | 19.21 Mrd. | |
-3.79% | 18.08 Mrd. | |
-38.57% | 17.71 Mrd. | |
+35.26% | 12.42 Mrd. | |
-24.61% | 8.23 Mrd. |
- Börse
- Aktien
- 900964 Aktie
- Unternehmen Neurocrine Biosciences, Inc.